NewsRoom Articles - Page 573 of 601

WednesdayOct 11, 2017 9:30 am

ChineseInvestors.com, Inc. (CIIX) Markets Hemp-Infused CBD Skin Care Line in China with Multi-Platform Strategy

CIIX’s goal is 100% growth, cost cuts and profitability in FY2018 after recording 76% YOY operating sales jump in FY2017 Valuation of CIIX “could explode with this huge potential market in China of 1.4 billion people,” according to investor relations director in SmallCapVoice interview Consilium Global Research projects CIIX sales will reach $14.8 million by FY2020 ChineseInvestors.com, Inc. (OTCQB: CIIX) is growing in numerous directions due to its diverse strategy of marketing, communications and product development both within China and to the global Chinese-speaking community. After recording YOY operating sales gains of 130% in investor relations and 57% in subscription…

WednesdayOct 11, 2017 9:30 am

India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease

Seeks patent on new therapy for drug that employs concentrations of THC Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://cnw.fm/UhYF1). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron…

TuesdayOct 10, 2017 12:53 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Bioabsorption Tech Boosting Development of CBD Products

Technology improves absorption of cannabidiol and bioactive compounds into the bloodstream It is now being used on all non-psychoactive cannabinoids and applied to edibles and health food products Patents have been awarded in the U.S. and Australia and are pending in 44 countries Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds. Its patent-protected technology has improved the ability of cannabinoid-products companies to deliver active ingredients to the body. With patents pending for tetrahydrocannabinol and other psychoactive cannabinoids (plus nicotine and non-steroidal anti-inflammatory drugs), the current technology…

TuesdayOct 10, 2017 9:00 am

Green Rush Offers Enticing Secondary Business Opportunities

CannabisNewsWire Editorial Coverage: Legal marijuana sales in North America hit $6.7 billion in 2016 – a 34 percent jump from the previous year, making it the fastest-growing industry on the planet, according to Arcview Market Research’s 2017 report on the marijuana market. The research firm expects those figures to soar to nearly $23 billion by 2021. Companies that provide products and services related to the broader cannabis economy enjoy huge growth potential as the industry continues its inevitable march toward full legalization, and few of them require touching a single leaf of the highly regulated plant. Companies such as SinglePoint,…

MondayOct 09, 2017 11:52 am

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Paving the Way as Biosynthesis Promises to Revolutionize Drug Development

Forbes predicts medical marijuana sales to reach $13.3 billion by 2020 Biotech/pharma market could surpass $20 billion by 2020, per estimates from Viridian Capital Advisors InMed’s biosynthesis process uses DNA and E. coli to produce cannabinoids that are identical to the 90+ found in nature The company’s pipeline drugs, focusing on rare dermatological diseases, glaucoma and topical pain treatments, are advancing toward clinical trials There may be many companies exploring cannabinoid biosynthesis, but one in particular stands out. InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) has created a revolutionary process that is poised to impact the cannabinoid market. It’s just one…

MondayOct 09, 2017 9:06 am

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Scaling Up to Meet Impending Spike in Cannabis Demand

Ever at the forefront of Canada’s cannabis market, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) was among the very first companies to obtain a cannabis production license in that country and has since been working to change the face of medical cannabis—both in Canada and globally. ABcann’s group of companies is working toward the aim of becoming the first cannabis pioneers to produce repeatable, standardized, plant-based medicines around the world. Every variable of ABcann’s cannabis growing, curing and harvesting process is computer-monitored and controlled. This high-tech indoor growing environment consistently yields a superior product that is clean, steady and repeatable—something…

FridayOct 06, 2017 1:41 pm

Algae Dynamics Corp. (ADYNF) Takes the Safe Road in Cannabis Delivery

Focused on developing remedies from cannabis oil Research programs in conjunction with Universities of Waterloo & Western Ontario Strategy to capture market share of non-smoke MMJ nutraceuticals To acquire the benefits of cannabis, there are many pathways, with some being distinctly safer than others. There are tinctures and topicals; there is dabbing; and there is vaping. There are drinks and digestibles and, of course, there is smoking. Over the last few decades, what some wits refer to as ‘puffing the magic dragon’ has emerged as the top delivery method for users of cannabis, but smoking harms nearly every organ of…

FridayOct 06, 2017 1:04 pm

EVIO, Inc. (EVIO) is “One to Watch”

Rapidly expanding network of analytical cannabis testing laboratories now serving five states Accurate, reliable lab results based on scientific principles using state-of-the-art facilities Analytical services include testing cannabis flowers, extracts and infused products EVIO, Inc. (OTCQB: EVIO), via the EVIO Labs division, is the nation’s leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation’s cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon…

FridayOct 06, 2017 1:04 pm

Skinvisible, Inc. (SKVI) is “One to Watch”

Patented technology enhances how topical and transdermal drugs and skin care products are delivered Polymer delivery vehicle can be tailored to almost any type of molecule including the medicinal components of hemp and marijuana 14 patents granted in the U.S. and internationally $65 billion market in dermatology, pharmaceutical and other healthcare industries offers strong growth opportunity Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their…

ThursdayOct 05, 2017 11:07 am

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Enters Agreement for Sustained Release Cannabinoid Formulation

Companies collaborating on development of patent-pending sustained release oral cannabinoid formulation Formulation doubles or triples time period in which cannabinoid doses maintain their therapeutic effects Formulation enables better regulation of dosing schedules and improvement of patient compliance Emblem Corp. (TSX.V: EMC) (OTC: EMMBF), a company licensed to cultivate and sell medical marijuana in Canada under the Access to Cannabis for Medical Purposes Regulations, has entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release formulation for cannabinoids. Through this agreement,…